<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01288378</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-65091-06093</org_study_id>
    <secondary_id>2010-020814-27</secondary_id>
    <secondary_id>MK-0991-070</secondary_id>
    <nct_id>NCT01288378</nct_id>
  </id_info>
  <brief_title>Empirical Versus Preemptive Antifungal Therapy</brief_title>
  <official_title>Empirical Versus Pre-emptive (Diagnostic-driven) Antifungal Therapy of Patients Treated for Haematological Malignancies or Receiving an Allogeneic Stem Cell Transplant. A Therapeutic Open Label Phase III Strategy Study of the EORTC Infectious Diseases and Leukemia Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients&#xD;
      with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their&#xD;
      cancer. It is not yet known whether caspofungin acetate is more effective when treatment&#xD;
      starts after development of a fever or after the infection is shown in laboratory test, chest&#xD;
      x-ray, or CT scan.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying the best time to start caspofungin&#xD;
      acetate therapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome&#xD;
      that is newly diagnosed or in first relapse.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare empirical approach (i.e., fever driven) versus preemptive approach (i.e.,&#xD;
           diagnostic driven), for starting antifungal therapy with caspofungin acetate, in&#xD;
           patients with acute myeloid leukemia or myelodysplastic syndrome who are starting&#xD;
           chemotherapy (for attaining remission induction) or myeloablation (to prepare for an&#xD;
           allogeneic hematopoietic stem cell transplantation) for newly diagnosed disease or&#xD;
           disease in first relapse.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate clinical validity and utility of a standardized Aspergillus PCR assay.&#xD;
&#xD;
        -  To evaluate clinical validity and utility of beta-D-glucan.&#xD;
&#xD;
        -  To determine the occurrence of single nucleotide polymorphisms (SNPs) and the predictive&#xD;
           value of SNPs for identifying patients at higher risk of developing invasive fungal&#xD;
           infection.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to institution, prior&#xD;
      allogeneic stem cell transplantation (yes vs no), and type of air flow (laminar air flow vs&#xD;
      high-efficiency particulate air). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm A (Empirical approach): Patients start caspofungin acetate treatment when one of the&#xD;
           following criteria are met:&#xD;
&#xD;
             -  Presence of unexplained persistent fever refractory to 4 full days of&#xD;
                broad-spectrum antibacterial therapy with any of the following regimens either&#xD;
                alone or in combination with an aminoglycoside or a glycopeptide:&#xD;
&#xD;
                  -  Ceftazidime&#xD;
&#xD;
                  -  Cefepime&#xD;
&#xD;
                  -  Piperacillin/tazobactam&#xD;
&#xD;
                  -  Imipenem-cilastatin&#xD;
&#xD;
                  -  Meropenem&#xD;
&#xD;
             -  New fever occurring &gt; 2 days after resolution of a first fever while continuing&#xD;
                broad-spectrum antibacterial therapy as defined above for which no obvious cause&#xD;
                has been documented and fungal infection cannot be excluded Patients receive&#xD;
                caspofungin acetate IV once daily. Treatment continues until neutrophil recovers.&#xD;
&#xD;
        -  Arm B (Preemptive approach): Patients start caspofungin acetate treatment when at least&#xD;
           one of the following criteria* are met:&#xD;
&#xD;
             -  Single plasma or serum galactomannan ELISA with index &gt; 0.5&#xD;
&#xD;
             -  New pulmonary infiltrate on chest x-ray and IFD cannot be readily excluded&#xD;
&#xD;
             -  New dense well-circumscribed lesions with or without a halo sign, on a CT scan,&#xD;
                consistent with IFD&#xD;
&#xD;
             -  Aspergillus sp. recovered by culture from sputum Patients receive caspofungin&#xD;
                acetate IV once daily. Treatment continues until neutrophil recovers.&#xD;
&#xD;
      NOTE: *These criteria are not sufficient to warrant preemptive caspofungin acetate therapy:&#xD;
      skin lesions evocative of IFD, sinusitis or orbititis, hepatosplenic abscesses (hypodensities&#xD;
      on CT scan), or unexplained persistent fever for more than 7 days or recurrent fever whatever&#xD;
      its duration.&#xD;
&#xD;
      All patients undergo blood sample collection periodically for the detection of galactomannan&#xD;
      and beta-D-glucan and for the detection of single nucleotide polymorphisms. Some patients&#xD;
      undergo blood sample collection for the detection of Aspergillus via PCR. An economic&#xD;
      evaluation is performed for cost-effectiveness analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">April 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 42 days after randomization</measure>
    <time_frame>6 weeks after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 84 days after randomization</measure>
    <time_frame>12 weeks after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of proven or probable invasive fungal disease (IFD) during the 42 and 84 days following randomization</measure>
    <time_frame>during 84 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proper management according to allocated treatment arm (i.e., appropriate administration of caspofungin acetate in compliance to protocol, and compliance to the treatment strategy) during the 42 and 84 days after randomization</measure>
    <time_frame>during 84 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival-free of fungal infection during the 42 and 84 days following randomization</measure>
    <time_frame>during 84 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse event [AE] and serious adverse event [SAE]) as assessed by CTCAE criteria v4.0</measure>
    <time_frame>during 84 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days under caspofungin treatment or under another antifungal treatment administered after caspofungin (evaluation will be done at day 42 and day 84 after randomization)</measure>
    <time_frame>at day 42 and day 84 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs related to the strategy for initiating and monitoring antifungal treatment during the 42 and 84 days following randomization</measure>
    <time_frame>during 84 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">556</enrollment>
  <condition>Fungal Infection</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Empirical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empirical approach (fever driven) for starting antifungal therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre-emptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-emptive approach (diagnostic driven) for starting antifungal therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caspofungin acetate</intervention_name>
    <description>intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.</description>
    <arm_group_label>Empirical</arm_group_label>
    <arm_group_label>Pre-emptive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)&#xD;
&#xD;
               -  Newly diagnosed disease or disease in first relapse after hematological remission&#xD;
                  lasting for a minimum of 6 months AND meets one of the following criteria:&#xD;
&#xD;
                    -  Starting remission-induction chemotherapy within 3 days prior to study&#xD;
                       randomization&#xD;
&#xD;
                    -  Starting myeloablative conditioning regimen to prepare for a first&#xD;
                       allogeneic hematopoietic stem cell transplantation within 3 days prior to&#xD;
                       study randomization&#xD;
&#xD;
          -  Planning a hospital admission for the duration of the neutropenic phase (ANC &lt; 0.5 x&#xD;
             10^9 /L)&#xD;
&#xD;
          -  Planning to receive oral or intravenous fluconazole for Candida prophylaxis at a dose&#xD;
             of 400 mg/day&#xD;
&#xD;
               -  Fluconazole is discontinued during caspofungin acetate administration&#xD;
&#xD;
          -  No previous or current history of proven or probable invasive fungal disease (IFD)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients muse use effective contraception during and for at least 3 months&#xD;
             after completion of study therapy&#xD;
&#xD;
          -  No current clinical diagnosis of pneumonia&#xD;
&#xD;
          -  No serious, uncontrolled, concomitant disease or comorbidity that, in the opinion of&#xD;
             the investigator, may compromise adherence to the study protocol&#xD;
&#xD;
          -  No history of allergy or any adverse reaction to echinocandin drugs (i.e., caspofungin&#xD;
             acetate, micafungin, or anidulafungin)&#xD;
&#xD;
          -  No hypersensitivity to caspofungin active substance or to any of the excipients&#xD;
&#xD;
          -  No inadequately treated infection&#xD;
&#xD;
          -  No documented HIV infection&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No history of liver cirrhosis or severe hepatic insufficiency (i.e., Child Pugh Class&#xD;
             C, D, or E)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent participation on another clinical trial using an investigational drug&#xD;
             for infectious diseases&#xD;
&#xD;
          -  No other concurrent systemic antifungal therapy (oral or intravenous)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Peter Donnelly</last_name>
    <role>Study Chair</role>
    <affiliation>Universitair Medisch Centrum St. Radboud - Nijmegen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Maertens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Cordonnier, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Henri Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Lodewyck</last_name>
    <role>Study Chair</role>
    <affiliation>AZ Sint-Jan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.Z. St. Jan</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk University</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Henri Mondor AP-HP</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Hurie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Wuerzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2011</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fungal infection</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with del(5q)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caspofungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

